KR102710552B1 - 항균 화합물 - Google Patents

항균 화합물 Download PDF

Info

Publication number
KR102710552B1
KR102710552B1 KR1020187001923A KR20187001923A KR102710552B1 KR 102710552 B1 KR102710552 B1 KR 102710552B1 KR 1020187001923 A KR1020187001923 A KR 1020187001923A KR 20187001923 A KR20187001923 A KR 20187001923A KR 102710552 B1 KR102710552 B1 KR 102710552B1
Authority
KR
South Korea
Prior art keywords
mmol
compound
alkyl
ring
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187001923A
Other languages
English (en)
Korean (ko)
Other versions
KR20180022826A (ko
Inventor
제롬 에밀 조르쥬 길레몽
마갈리 매들린 시몬 모떼
피에르 쟝-마리 베르나르 라보이송
압델라 타리
Original Assignee
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56289523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102710552(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 filed Critical 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니
Publication of KR20180022826A publication Critical patent/KR20180022826A/ko
Application granted granted Critical
Publication of KR102710552B1 publication Critical patent/KR102710552B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020187001923A 2015-07-02 2016-07-01 항균 화합물 Active KR102710552B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15174936 2015-07-02
EP15174936.3 2015-07-02
EP16174718.3 2016-06-16
EP16174718 2016-06-16
EP16174713 2016-06-16
EP16174713.4 2016-06-16
PCT/EP2016/065499 WO2017001660A1 (en) 2015-07-02 2016-07-01 Antibacterial compounds

Publications (2)

Publication Number Publication Date
KR20180022826A KR20180022826A (ko) 2018-03-06
KR102710552B1 true KR102710552B1 (ko) 2024-09-25

Family

ID=56289523

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187001923A Active KR102710552B1 (ko) 2015-07-02 2016-07-01 항균 화합물
KR1020187002072A Ceased KR20180022833A (ko) 2015-07-02 2016-07-01 항균성 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187002072A Ceased KR20180022833A (ko) 2015-07-02 2016-07-01 항균성 화합물

Country Status (29)

Country Link
US (6) US10364232B2 (enExample)
EP (3) EP3316969B1 (enExample)
JP (3) JP2018519302A (enExample)
KR (2) KR102710552B1 (enExample)
CN (3) CN113980015A (enExample)
AU (3) AU2016287477B2 (enExample)
BR (1) BR112017028318B1 (enExample)
CA (2) CA2986326A1 (enExample)
CL (1) CL2017003404A1 (enExample)
CO (1) CO2017013408A2 (enExample)
DK (1) DK3316969T3 (enExample)
EA (2) EA201890201A1 (enExample)
ES (1) ES2914681T3 (enExample)
HK (1) HK1249468A1 (enExample)
HR (1) HRP20220339T1 (enExample)
IL (2) IL256391B (enExample)
LT (1) LT3316969T (enExample)
MA (1) MA42293A (enExample)
MD (1) MD3316969T2 (enExample)
MX (2) MX2017016789A (enExample)
PE (1) PE20180520A1 (enExample)
PH (2) PH12017502297A1 (enExample)
PL (1) PL3316969T3 (enExample)
RS (1) RS63201B1 (enExample)
SI (1) SI3316969T1 (enExample)
SM (1) SMT202200220T1 (enExample)
UA (1) UA125171C2 (enExample)
WO (2) WO2017001660A1 (enExample)
ZA (1) ZA201708692B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
EP3760625B1 (en) 2015-07-02 2024-03-27 F. Hoffmann-La Roche AG Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
PL3316969T3 (pl) 2015-07-02 2022-06-20 Janssen Sciences Ireland Unlimited Company Związki przeciwbakteryjne
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
CA3012560A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CA3012624A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
SG11201807982UA (en) 2016-03-16 2018-10-30 Kura Oncology Inc Substituted inhibitors of menin-mll and methods of use
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
MA47420A (fr) * 2017-02-06 2019-12-11 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
JP2020537667A (ja) 2017-10-17 2020-12-24 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
RU2680972C1 (ru) * 2018-02-13 2019-03-01 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков
US20210009583A1 (en) * 2018-03-12 2021-01-14 University Of Notre Dame Du Lac Deuterated imidazopyridines
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
KR102839500B1 (ko) 2018-08-22 2025-07-28 아셰뉴론 에스아 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염
CN109503631A (zh) * 2018-12-29 2019-03-22 中国医学科学院医药生物技术研究所 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用
WO2020243224A1 (en) * 2019-05-28 2020-12-03 Shionogi & Co., Ltd. A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
KR102076958B1 (ko) 2019-06-24 2020-02-13 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
ES2978573T3 (es) 2019-09-13 2024-09-16 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos
KR20220075335A (ko) 2019-09-30 2022-06-08 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균 화합물
KR20220071199A (ko) 2019-09-30 2022-05-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 4-퀴놀리논 항균 화합물
CA3162532A1 (en) 2019-12-27 2021-07-01 Augusto Eugenio Pardal Filipe Antibacterial quinolines
AU2022237769A1 (en) 2021-03-16 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN117440958A (zh) * 2021-03-17 2024-01-23 爱尔兰詹森科学公司 抗菌化合物
MX2023010948A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2024000111A (es) 2021-06-29 2024-01-19 Tecnimede Sociedade Tecnico Medicinal Sa Compuestos heterociclicos para el tratamiento de tuberculosis.
JP2024540052A (ja) 2021-10-28 2024-10-31 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 細菌感染の治療に使用するためのイミダゾピリジンアミド及び関連化合物
CN114957954B (zh) * 2022-05-16 2024-08-20 万华化学集团股份有限公司 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用
AU2023292503A1 (en) * 2022-06-15 2024-10-31 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127269A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido spirocyclic amide and sulfonamide derivatives
WO2015014993A2 (en) 2013-08-02 2015-02-05 Institut Pasteur Korea Anti-infective compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT792273E (pt) 1994-11-15 2003-06-30 Upjohn Co Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas
DE69614847T2 (de) 1995-05-11 2002-04-04 Pharmacia & Upjohn Co., Kalamazoo Spirocyclische und bicyclische diazinyl- und carbazinyloxazolidinone
MXPA05001052A (es) 2002-07-25 2005-04-08 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores micobacterianos.
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
NZ587096A (en) 2008-03-26 2011-11-25 Global Alliance For Tb Drug Dev Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
AU2009294850B2 (en) 2008-09-22 2015-07-02 Oregon Health & Science University Methods for detecting a Mycobacterium tuberculosis infection
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
CN106866667B (zh) 2009-11-05 2019-11-15 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
RU2576662C2 (ru) * 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EA201490537A1 (ru) 2011-09-01 2014-07-30 АйАрЭм ЭлЭлСи СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
BR112014004560A2 (pt) 2011-09-01 2017-04-04 Irm Llc compostos e composições como inibidores de c-kit quinase
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CA2879460C (en) * 2012-07-18 2021-10-19 Garrett MORASKI 5,5-heteroaromatic anti-infective compounds
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
US10080749B2 (en) 2014-11-03 2018-09-25 The Regents Of The University Of California Multi-drug therapies for tuberculosis treatment
PL3316969T3 (pl) * 2015-07-02 2022-06-20 Janssen Sciences Ireland Unlimited Company Związki przeciwbakteryjne
CN109415349A (zh) 2016-06-16 2019-03-01 爱尔兰詹森科学公司 杂环化合物作为抗细菌剂
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127269A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido spirocyclic amide and sulfonamide derivatives
JP2015508786A (ja) 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体
WO2015014993A2 (en) 2013-08-02 2015-02-05 Institut Pasteur Korea Anti-infective compounds

Also Published As

Publication number Publication date
ES2914681T3 (es) 2022-06-15
SI3316969T1 (sl) 2022-05-31
IL256391A (en) 2018-02-28
EP4074378A1 (en) 2022-10-19
CN108235704A (zh) 2018-06-29
HK1249468A1 (zh) 2018-11-02
CL2017003404A1 (es) 2018-05-11
DK3316969T3 (da) 2022-05-02
PH12017502297A1 (en) 2018-06-25
AU2016287477B2 (en) 2021-10-21
PH12017502298B1 (en) 2018-06-11
WO2017001660A1 (en) 2017-01-05
RS63201B1 (sr) 2022-06-30
JP7099824B2 (ja) 2022-07-12
CN113980015A (zh) 2022-01-28
IL256391B (en) 2021-03-25
JP2022043078A (ja) 2022-03-15
AU2016287478B2 (en) 2021-10-21
JP2018524339A (ja) 2018-08-30
SMT202200220T1 (it) 2022-07-21
US11180472B2 (en) 2021-11-23
MX386598B (es) 2025-03-19
CO2017013408A2 (es) 2018-05-31
NZ737408A (en) 2024-07-26
ZA201708692B (en) 2024-07-31
CN107708809A (zh) 2018-02-16
EP3316968A1 (en) 2018-05-09
HK1254677A1 (zh) 2019-07-26
PE20180520A1 (es) 2018-03-14
EP3316969A1 (en) 2018-05-09
UA125171C2 (uk) 2022-01-26
US20240132470A1 (en) 2024-04-25
CN108235704B (zh) 2021-10-26
US20200239434A1 (en) 2020-07-30
US20230014173A1 (en) 2023-01-19
US20190330189A1 (en) 2019-10-31
HRP20220339T1 (hr) 2022-05-13
BR112017028318A2 (pt) 2018-09-04
PL3316969T3 (pl) 2022-06-20
MA42293A (fr) 2018-05-09
US20180186768A1 (en) 2018-07-05
MX2017016788A (es) 2018-07-06
JP7516338B2 (ja) 2024-07-16
MX2017016789A (es) 2018-06-11
IL256379A (en) 2018-02-28
AU2022200385A1 (en) 2022-02-17
CA2986331A1 (en) 2017-01-05
WO2017001661A1 (en) 2017-01-05
EA201890204A1 (ru) 2018-06-29
LT3316969T (lt) 2022-03-25
CA2986326A1 (en) 2017-01-05
JP2018519302A (ja) 2018-07-19
AU2022200385B2 (en) 2024-06-13
AU2016287478A1 (en) 2017-11-30
PH12017502298A1 (en) 2018-06-11
MD3316969T2 (ro) 2022-07-31
KR20180022833A (ko) 2018-03-06
EA201890201A1 (ru) 2018-06-29
US11866419B2 (en) 2024-01-09
EP3316969B1 (en) 2022-03-02
BR112017028318B1 (pt) 2024-02-20
KR20180022826A (ko) 2018-03-06
NZ774761A (en) 2024-09-27
AU2016287477A1 (en) 2017-11-30
US20180155341A1 (en) 2018-06-07
US10364232B2 (en) 2019-07-30

Similar Documents

Publication Publication Date Title
KR102710552B1 (ko) 항균 화합물
AU2017286368B2 (en) Heterocyclic compounds as antibacterials
KR20190018681A (ko) 항균제로서의 헤테로고리 화합물
HK40004907A (en) Heterocyclic compounds as antibacterials
OA18504A (en) Antibacterial compounds.
OA19129A (en) Heterocyclic compounds as antibacterials.
HK1254677B (zh) 抗细菌化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210630

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230717

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240624

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240923

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240923

End annual number: 3

Start annual number: 1

PG1601 Publication of registration